.Attribute Medication, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after a mean follow-up of 11 months, people along with metastatic intestinal lumps that got biomarker-matched therapies based on flowing growth DNA profiling presented a better professional perk than those getting unrivaled therapy.